Annals of Internal MedicinePharmacologic Treatments for Females with Menopausal Vasomotor Symptoms: A Clinical Guideline from the American College of Physicians

✅ Guideline Update

Published October 6, 2026, this ACP guideline addresses pharmacologic treatment of vasomotor symptoms in perimenopausal and postmenopausal patients seeking outpatient care. Systematic reviews and a network meta-analysis informed GRADE recommendations incorporating benefits, harms, preferences, and economic value. Estrogen-based therapy receives a strong first-line recommendation; subsequent options are conditional. The hierarchy is not simply an efficacy ranking: costs influence neurokinin receptor antagonist placement. Genitourinary symptom treatment is outside scope, and evidence is limited for perimenopausal and higher-risk patients.

Clinical Considerations

• First-line: estrogen plus progestogen with a uterus; estrogen alone without a uterus. Both carry high-certainty evidence; progestogen provides endometrial protection.
• Second-line: desvenlafaxine or venlafaxine for first-line contraindications or intolerance; ACP assigns a conditional recommendation with moderate-certainty evidence.
• Third-line: escitalopram, paroxetine, or gabapentin have low-certainty evidence; elinzanetant and fezolinetant have moderate-certainty evidence. Recommendations are conditional.
• Neurokinin receptor antagonists occupy third-line partly because of cost and economic value, not because ACP found them ineffective.
• Trials had a median 12-week duration and commonly excluded higher-risk patients; rare-event findings do not establish long-term cardiovascular or cancer safety.
• No recommendation was issued for oxybutynin, estrogen plus bazedoxifene, or progestogen alone because harms evidence was insufficient, not because efficacy was disproven.

Practice Applications

• Review uterine status, contraindications, comorbidities, preferences, affordability, and access before selecting therapy; distinguish strong first-line guidance from conditional alternatives.
• Monitor liver tests with fezolinetant at baseline, monthly for three months, and at six and nine months, as specified in the supplied guideline.
• Evaluate response after 8 to 12 weeks; use the lowest effective dose and periodically reassess benefits, risks, and continued treatment need.
• Avoid interpreting similar route-specific efficacy as equivalent safety, or treating the described 3-to-5-year practice pattern as a mandatory stopping rule.
• Recognize exclusions: current breast cancer or its hormonal treatment, premature ovarian failure, and patients already receiving gender-transition hormones require separate guidance.